Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | DNA topoisomerase IB, large subunit, putative | 0.0169 | 0.208 | 0.5 |
Toxoplasma gondii | DNA topoisomerase I, putative | 0.0226 | 0.4207 | 0.5 |
Echinococcus granulosus | DNA topoisomerase 1 | 0.0226 | 0.4207 | 1 |
Echinococcus granulosus | adam 17 protease | 0.0199 | 0.3204 | 0.7616 |
Plasmodium vivax | topoisomerase I, putative | 0.0226 | 0.4207 | 0.5 |
Echinococcus multilocularis | DNA topoisomerase 1 | 0.0226 | 0.4207 | 1 |
Brugia malayi | DNA topoisomerase I | 0.0226 | 0.4207 | 0.5 |
Schistosoma mansoni | DNA topoisomerase type I | 0.0226 | 0.4207 | 1 |
Leishmania major | DNA topoisomerase IB, large subunit | 0.0169 | 0.208 | 0.5 |
Schistosoma mansoni | ADAM17 peptidase (M12 family) | 0.0181 | 0.2528 | 0.2103 |
Plasmodium falciparum | topoisomerase I | 0.0226 | 0.4207 | 0.5 |
Echinococcus multilocularis | adam 17 protease | 0.0181 | 0.2528 | 0.6008 |
Trypanosoma brucei | DNA topoisomerase IB, large subunit | 0.0169 | 0.208 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC200 (functional) | > 10000 nM | Compound was tested for the effect on the formation of protein-DNA complex in P388 cells investigated by the K+/SDS method | ChEMBL. | 10743939 |
EC50 (functional) | > 3000 nM | Inhibitory effect on topoisomerase-I mediated DNA cleavage using supercoiled pBR322 plasmid DNA | ChEMBL. | 10743939 |
EC50 (functional) | > 50 uM | Tested for inhibitory effect on topoisomerase-II mediated DNA cleavage using super coiled pBR322 plasmid DNA | ChEMBL. | 10743939 |
IC50 (functional) | = 3.5 nM | The compound was tested for the cytotoxic activity against murine leukemia cells (P388) | ChEMBL. | 10743939 |
IC50 (functional) | = 73 nM | Tested for cytotoxic activity against human stomach cancer cells (MKN-45) | ChEMBL. | 10743939 |
IC50 (binding) | > 200 uM | Inhibitory effect on protein kinase C using histone II-As as substrate | ChEMBL. | 10743939 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.